[Comment] Olorofim: addressing unmet needs of patients with difficult-to-treat fungal infections

Olorofim is a first-in-class compound from the novel orotomide class of antifungal agents. Among antifungals in the development pipeline,1 olorofim stands out because of its potent in vitro activity against various difficult-to-treat fungi, including moulds such as azole-resistant Aspergillosis spp, Scedosporium spp, and Lomentospora prolificans, as well as the dimorphic fungi Histoplasma spp and Coccidioides spp. Notable drawbacks include its lack of activity against yeasts and Mucorales and its higher minimum inhibitory concentrations for the Fusarium solani species complex and F dimerum than for other Fusarium spp.